Targeted Therapies for Adrenocortical Carcinoma: IGF and Beyond

Overview

Journal Horm Cancer

Date 2011 Dec 16

PMID 22170383

Citations 14

Authors

Michael J Demeure

Kimberly J Bussey

Lawrence S Kirschner

Affiliations

Soon will be listed here.

Abstract

Standard chemotherapy for adrenocortical cancer currently is under evaluation in the context of the recently completed FIRM-ACT evaluating the combination of mitotane with either streptozocin or etoposide, cisplatin, and doxorubicin. New agents are eagerly sought by the ACC community that hopes to make progress against this deadly disease. Investigators have begun to dissect the molecular and genomic context of ACC with a goal of identifying potential novel therapeutic agents. One gene consistently overexpressed in ACC is insulin growth factor type 2. Targeting its receptor IGF1R has shown encouraging results in ACC cell lines and against murine xenografts. As a result, clinical trials to evaluate agents targeting the IGF1R have been done including mitotane and IMC-A12 (a monoclonal antibody) and the GALACCTIC trial that has just completed accrual to evaluate OSI-906, a small molecule IGF1R antagonist. On the horizon are other agents targeting other tyrosine kinases, including EGF and FGF, and novel strategies such as individualized tumor analysis to select treatment.

Citing Articles

Effects of linsitinib on M22 and IGF:1-treated 3D spheroids of human orbital fibroblasts.

Hikage F, Suzuki M, Sato T, Umetsu A, Ogawa T, Nishikiori N Sci Rep. 2025; 15(1):384.

PMID: 39747159 PMC: 11697574. DOI: 10.1038/s41598-024-83193-x.

Expression of EMP 1, 2, and 3 in Adrenal Cortical Neoplasm and Pheochromocytoma.

Cha Y, Koo J Int J Mol Sci. 2023; 24(16).

PMID: 37629198 PMC: 10455306. DOI: 10.3390/ijms241613016.

Histological scores and tumor size on stage II in adrenocortical carcinomas.

Oliveira R, Martins M, Moreno C, Almeida R, Carvalho J, Teixeira P Rare Tumors. 2021; 13:20363613211026494.

PMID: 34262677 PMC: 8243092. DOI: 10.1177/20363613211026494.

Efficacy of oral metformin in a patient with metastatic adrenocortical carcinoma: Examination of mechanisms and therapeutic implications.

Peixoto R, Gomes L, Sousa T, Racy D, Shigenaga M, Nagourney R Rare Tumors. 2019; 10:2036361317749645.

PMID: 31508193 PMC: 5811989. DOI: 10.1177/2036361317749645.

Pathway Implications of Aberrant Global Methylation in Adrenocortical Cancer.

Legendre C, Demeure M, Whitsett T, Gooden G, Bussey K, Jung S PLoS One. 2016; 11(3):e0150629.

PMID: 26963385 PMC: 4786116. DOI: 10.1371/journal.pone.0150629.

References

Folkman J . Tumor angiogenesis: a possible control point in tumor growth. Ann Intern Med. 1975; 82(1):96-100. DOI: 10.7326/0003-4819-82-1-96. View

Gaujoux S, Tissier F, Groussin L, Libe R, Ragazzon B, Launay P . Wnt/beta-catenin and 3',5'-cyclic adenosine 5'-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors. J Clin Endocrinol Metab. 2008; 93(10):4135-40. DOI: 10.1210/jc.2008-0631. View

Seki M, Tanaka K, Konishi M, Fukunari H, Iwama T, Miyaki M . Loss of normal allele of the APC gene in an adrenocortical carcinoma from a patient with familial adenomatous polyposis. Hum Genet. 1992; 89(3):298-300. DOI: 10.1007/BF00220544. View

Takahari D, Yamada Y, Okita N, Honda T, Hirashima Y, Matsubara J . Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer. Oncology. 2008; 76(1):42-8. DOI: 10.1159/000178164. View

Sierra J, Cepero V, Giordano S . Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer. 2010; 9:75. PMC: 2864216. DOI: 10.1186/1476-4598-9-75. View

Ronchi C, Sbiera S, Kraus L, Wortmann S, Johanssen S, Adam P . Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy. Endocr Relat Cancer. 2009; 16(3):907-18. DOI: 10.1677/ERC-08-0224. View

Iiizumi M, Liu W, Pai S, Furuta E, Watabe K . Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy. Biochim Biophys Acta. 2008; 1786(2):87-104. PMC: 2645343. DOI: 10.1016/j.bbcan.2008.07.002. View

Fallo F, Pilon C, Barzon L, Pistorello M, Pagotto U, Altavilla G . Paclitaxel is an effective antiproliferative agent on the human NCI-H295 adrenocortical carcinoma cell line. Chemotherapy. 1998; 44(2):129-34. DOI: 10.1159/000007104. View

Cunningham M, Thomas H, Marks C, Green M, Fan Z, Modjtahedi H . Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells. Int J Oncol. 2008; 33(5):1107-13. View

10.

Kroiss M, Quinkler M, Johanssen S, van Erp N, Lankheet N, Pollinger A . Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. J Clin Endocrinol Metab. 2012; 97(10):3495-503. DOI: 10.1210/jc.2012-1419. View

11.

Turner N, Grose R . Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010; 10(2):116-29. DOI: 10.1038/nrc2780. View

12.

Kamio T, Shigematsu K, Sou H, Kawai K, TSUCHIYAMA H . Immunohistochemical expression of epidermal growth factor receptors in human adrenocortical carcinoma. Hum Pathol. 1990; 21(3):277-82. DOI: 10.1016/0046-8177(90)90227-v. View

13.

Quinkler M, Hahner S, Wortmann S, Johanssen S, Adam P, Ritter C . Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab. 2008; 93(6):2057-62. DOI: 10.1210/jc.2007-2564. View

14.

Barnes C, Ohshiro K, Rayala S, El-Naggar A, Kumar R . Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res. 2007; 13(14):4291-9. DOI: 10.1158/1078-0432.CCR-06-2040. View

15.

Loilome W, Joshi A, ap Rhys C, Piccirillo S, Vescovi A, Angelo V . Glioblastoma cell growth is suppressed by disruption of Fibroblast Growth Factor pathway signaling. J Neurooncol. 2009; 94(3):359-66. DOI: 10.1007/s11060-009-9885-5. View

16.

West A, Neale G, Pounds S, Figueredo B, Rodriguez Galindo C, Pianovski M . Gene expression profiling of childhood adrenocortical tumors. Cancer Res. 2007; 67(2):600-8. DOI: 10.1158/0008-5472.CAN-06-3767. View

17.

DAgostino Sr R . Changing end points in breast-cancer drug approval--the Avastin story. N Engl J Med. 2011; 365(2):e2. DOI: 10.1056/NEJMp1106984. View

18.

Xin X, Abrams T, Hollenbach P, Rendahl K, Tang Y, Oei Y . CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice. Clin Cancer Res. 2006; 12(16):4908-15. DOI: 10.1158/1078-0432.CCR-06-0957. View

19.

Zetter B . The scientific contributions of M. Judah Folkman to cancer research. Nat Rev Cancer. 2008; 8(8):647-54. DOI: 10.1038/nrc2458. View

20.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-42. DOI: 10.1056/NEJMoa032691. View